Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | −$0.18 | — | $4.05M | −76.3% | −$0.17 |
| Q1 FY26ended Mar 31, 2026 | May 14, 2026 | −$0.14 | — | $8.32M | +96.3% | −$0.22 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.03 | — | $44.85M | +788.2% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.19 | — | $8.96M | +37.6% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.12 | — | $17.08M | +133.3% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.15 | — | $4.24M | −57.5% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.12 | — | $5.05M | −45.0% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.17 | — | $6.51M | −1.4% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Abcellera Biologics shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$0.13 |
| — |
| $7.32M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.14 | — | $9.95M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.16 | — | $9.18M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$0.10 | — | $6.60M | — | — |